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ABSTRACT
The effect of propranolol dosing rate on /3-blockade was studied
in human volunteers after administration of a conventional tablet
and a sustained release capsule. The slope of the plot of the
percentage of reduction in the heart rate against log plasma
propranolol concentration was significantly greater after admin-
istration of a sustained release capsule than after administration
of a conventional tablet. A marked leftward shift of the plasma
concentration-response curve was also observed in rabbits as
the infusion rate was decreased over the same infusion period.
This shift was not altered by pretreatment with 6-hydroxydopa-
mine and plasma catecholamine levels were not affected by the
rate of infusion, indicating that the contribution of sympathetic
activation to the effect was minimal. By contrast to the anticlock-
wise hysteresis of the temporal response after propranolol, no
such hysteresis was found with the more hydrophilic fl-adreno-
captor antagonist atenolol, or was there any leftward shift in the
plasma concentration- response relationship. Data from the iso-
lated guinea pig atrial preparation also showed anticlockwise
hysteresis and a leftward shift of the concentration-response
curve at a low propranolol input rate, whereas no shift was
observed with more hydrophilic $-blockers such as atenolol,
pindolol and metoprolol. An initial response was observed after
5 to 1 0 mm of treatment but continued exposure to a constant
concentration of propranolol over 40 mm resulted in a further
increase in effect. The decrease in heart rate induced by pro-
pranolol was observed in the presence of a large dose of the
hydrophilic /3-blocker, CGP-1 21 77 [(±)-4-(3-t-butylamino-2-hy-
droxypropoxy)-benzimidazole-2-one hydrochloridej, but no heart
responses were observed with the hydrophilic agonist, isopro-
terenol, and the hydrophilic antagonist, atenolol, under the same
conditions. These data suggest that the dosing rate-dependent
concentration-response relationship is due to the presence of
two distinct fl-adrenoceptor binding sites on the surface mem-
brane which differ in lipophilic characteristics. Only lipophilic
drugs would be accessible to the more lipophilic site which is
responsible for a delayed response.
It is generally considered that an elicited pharmacological
response is dependent on the drug concentration at the bio-
phase, often assumed to be a direct reflection of the plasma
level, and the concentration-response relationship is fixed and
independent of the manner in which it is achieved. Recently,
however, the rate of drug administration has been shown to be
an important determinant of the effects produced by calcium
channel blockers, such as nifedipine (Kleinbloesem et at., 1987)
and felodipine (Cohen et at., 1990). Also, different relationships
between plasma level and beta adrenoceptor blocking activity
have been reported for alprenolol (Collste et at., 1979), meto-
prolol (Collste et al., 1980) and propranolol (von Bahr et at.,
1982), dependent upon the administered dose. Because the
elimination half-life ofpropranolol is only about 4 to 6 hr (Nace
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and Wood, 1987), a sustained-release preparation (LA) has
been developed as a once-daily treatment for patients with
hypertension (Serlin et at., 1983), cardiac arrhythmias and
angina pectoris (Parker et al., 1982). Previous studies have
shown that the systemic bioavailability and plasma levels after
LA are significantly lower (40-70%) than those after adminis-
tration of a PL (McAinsh et at., 1981), due, in part, to reduced
absorption (Takahashi et at., 1990b). However, no significant
differences between PL and LA with respect to the peak or
duration of fl-blocking activity were observed (Cales et at.,
1989), suggesting that the effectiveness of LA is greater (lower
plasma propranolol level for equally effective 13-blockade) than
that of PL. It is possible that these previous observations reflect
a dosing rate effect on the relationship between plasma pro-
pranolol levels and fl-blockade. The purpose of this study,
therefore, was to determine the effect of drug delivery rate of
propranolol on 3-blockade in humans, rabbits and isolated
guinea pig atria. Additionally, inasmuch as such a dosing rate-
dependent relationship was established, possible determining
factors were also investigated.
was defined as:
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METHODS
Materials. (±)-Propranolol hydrochloride and (±)-atenolol were
supplied by ICI-Pharma (Osaka, Japan), (±)-pindolol by Sankyo Phar-
maceutical Co. Ltd. (Tokyo, Japan) and -penbutolol sulfate by Hoechst
Japan Ltd. (Tokyo, Japan). -Isoprothrenol-(+)-bitartrate,
(±)-metoprolol-(+)-tartrate, GTP and 6-hydroxydopamine were ob-
tamed from Sigma Chemical Co. (St. Louis, MO), whereas (±)-CGP-
12177A hydrochloride [(±)-4-(3-t-butylamino-2-hythoxypropoxy)-ben-
zimidazole-2-one hydrochloride] was purchased from Research Bio-
chemical Inc. (Natick, MA). -[3HJCGP-12177 (specific activity, 1.87
TBciJmmol) was supplied by Amersham International Ltd. (Buckingh-
amshire, UK), (+)-quinidine sulfate were from Nakarai Chemicals Co.
(Kyoto, Japan), -noradrenaline and -adrenaline were from Tokyo Kasei
(Tokyo, Japan) and 3,4-dihydroxybenzylamine hydrobromide was ob-
tamed from Aldrich Chemical Co. Inc. (Milwaukee, WI). All other
chemicals used were of reagent grade.
Pharmacodynamics in human volunteers. Six subjects (two
females and four males; age 25-34 years; mean, 28.2 year; weight, 45-
68 kg; mean, 54.5 kg) participated in the study. None of the subjects
showed any abnormalities of their ECG, urinalysis and routine bio-
chemical tests. The levels of a4,ha-1-acid glycoprotein, determined by
a radial immunodiffusion method (NorPartigen a4,ha-1-acid glycopro-
tom, Hoechst Japan Ltd., Tokyo, Japan), were within the normal range
(0.541 ± 0.129 mg/ml, mean ± S.D.). The study was carried out
according to a single-dose, two-way crossover design, after obtaining
written consent. All subjects, fasted for 10 hr before and until 2 hr
after dosing, were given either three conventional 20-mg PLs or one
60-mg LA p.o. with 200 ml of water, on separate occasions 4 weeks
apart. During the study, graded stress testing on a treadmill was
performed at either 2, 4, 8 and 24 hr or 3, 6, 10 and 24 hr after taking
PL or LA, respectively. Each subject underwent the treadmill exercise
test before the study proper, starting from stage I (1.7 mph at 10%
grade) and increasing to stage Ill (3.4 mph at 14% grade), to become
familiar with the procedure and to determine the submaximal exercise
load which raised heart rate to over 155 beats/mm. During the exercise
test, heart rate was monitored continuously by ECG. The degree of -
blockade was assessed from the %R of the heart rate defined as:
%R = (EHRO EHR/EHRO) x 100
where EHRO and EHR are the heart rates measured on completion of
submaximal exercise loading in the absence and the presence of pro-
pranolol, respectively. Just before each treadmill exercise, blood was
collected into heparinized tubes and the plasma was separated and
stored at -20C until analyzed.
Pharmacodynamics in rabbits. 3-Blockade by propranolol was
measured as the inhibition of isoproterenol-induced tachycardia in four
male Japanese White rabbits (Tokyo Jikken Dobutu, Tokyo, Japan),
weighing 3.1 to 3.7 kg. ECG leads were connected to each limb and the
control heart rate response to an i.v. bolus injection of isoproterenol
(1.0 g/kg) was recorded from Lead II. Subsequently, the effect of the
duration ofpropranolol infusion was investigated. Propranolol (2.0 mgI
kg in normal saline) was infused into a marginal ear vein with an
infusion pump (model JP-S, Fume Sci., Tokyo, Japan) over 0.5 and 5
hr, on separate occasions at least 1 week apart. The %R by isoproterenol
%R = [(IHR - IHR)/IHR,) x 100 (2)
where IHR, and IHR are the heart rates increased by isoproterenol in
the absence and presence of propranolol, respectively. Response deter-
minations and blood sampling from a marginal ear vein of the other
ear were performed at 0, 0.5, 1, 2, 3, 4 and 6 hr after completion of drug
administration. Plasma was separated by centrifugation at 1760 x g
for 2 mm and stored at -20C until analyzed.
In order to differentiate between the effects of infuSion rate and
duration of infusion on fl-blockade, propranolol (0.4, 2 and 4 mg/kg)
was infused over a 30-mm infusion period on three separate occasions.
The schedule for fl-blockade determination and blood sampling was
similar to that used in the first experiment. In addition, atenolol (0.4
and 2 mg/kg) was also infused for 30 mm on a separate occasion with
fl-response measurement and blood sampling being obtained over 6 hr.
To determine plasma norepinephrine and epinephrine concentrations,
blood samples were collected into heparmnized tubes, containing 2 mg
of sodium EDTA at 0, 0.5, 1, 2, 3, 4 and 6 hr after completion of the
propranolol infusion.
The effect of sympathetic-denervation on the relationship between
the dosing rate and fl-blockade of propranolol was evaluated in three
rabbits pretreated with 6-hydroxydopamine, dissolved in normal saline
containing 0.25% w/v ascorbic acid. The pretreatment schedule con-
sist&1 of i.v. administration of 1, 3, 5, 10, 11 and 20 mg/kg 6, 5, 4, 3, 2
and 1 days, respectively, before the Study with propranolol (Kostrzewa
and Jacobowitz, 1974). Seven days after initiation of 6-hydroxydopa-
mine treatment, propranolol (0.4 or 4 mg/kg) was infused over 30 mm.
Blood sampling and beta responsive determinations were performed up
to 6 hr after completion of drug administration, as described above.
Pharmacodynamics in isolated guinea pig atrium. Male Har-
tley guinea pigs (250-400 g) were sacrificed, the heart was excised and
extraneous connective tissue was removed. The spontaneously beating
atrium was suspended vertically in an organ bath containing 10 ml of
physiological salt solution of the following composition (millimolar);
NaC1, 135; KC1, 3; CaCl2, 2; MgCl2, 1; NaHCO3, 15; glucose, 5.6; sodium-
EDTA, 0.022; and ascorbic acid, 0.057 (Tatsuno et at., 1976), main-
tamed at 35 ± 2C and bubbled with 95% 02-5% CO2. Isometric
contractions and heart rate of the atrial preparation were measured
with a force-displacement transducer (Toyo Baldwin, Tokyo, Japan)
and recorded on an oscillograph (model WT-625G, Nihon Kohden,
Tokyo, Japan). The atrium was allowed to stabilize in the physiological
salt solution for about 30 mm before use, after which two control
responses to 3 M isoproterenol were determined (the first value was
not used). The degree of beta blockade (%R), was obtained from the
relationship:
%R=(HR,-HR,/HIL,,)x 100
where HR and HR, are the heart rates produced by addition of 3
MM isoproterenol in the absence and the presence of propranolol,
respectively. The HR,, values were determined in 10- and 100-ml
volumes of physiological salt solution and did not differ significantly.
(1) The atrium was washed for at least 30 mm until the heart rate
returned to, or almost to, the base-line level and then it was subjected
to the subsequent treatments. First the propranolol concentration of
the bathing solution was increased in a stepwise fashion every 5 mm
over 30 mm to a final level of 0.15 sM. After the final propranolol
addition, the extent of the beta response was determined at 5-mm
intervals after the dilution of the bathing solution with physiological
saline containing 3 M isoproterenol, sufficient to yield propranolol
concentrations of 0.1, 0.05, 0.03 and 0.015 tM, respectively, in a final
volume of 100 ml. The atrial preparation was then washed rapidly and
its (control) response to 3 MM isoproterenol was again determined.
After a further washout phase, the stepwise additions of propranolol
and subsequent dilution were repeated at double the respective pro-
pranolol concentrations. On a separate occasion, the time course of
beta response to 3 zM isoproterenol was also determined after each
stepwise addition of propranolol as well as during the subsequent
dilution step. Similar dilution studies were also performed with four
other fl-blockers of differing lipophilicity. The drugs were administered
every 5 mm over 30 mm to provide final concentrations of 0.05 and 1.0
M for pindolol and penbutolol, 0.15 and 0.3 M for metoprolol and
0.5 and 1.0 ,M for atenolol. The 5-mm stepwise dilutions were made
until the concentration of the drug was 10% of its initial value.
The effect of duration of propranolol treatment on fl-blockade was also
investigated. First, the control response to 3 iM isoproterenol was
established followed by rapid washout and the addition of propranolol
at 0, 5 and 10 mm to give levels of 0.05, 0.1 and 0.15 tiM, respectively.
After the final addition step, beta responsiveness was again determined.
A further washout and control heart rate measurement were then
determined and the propranolol additions were again made but with fi-
blockade only being measured 10 mm subsequent to the final increment
in the propranolol level. The described washout-propranolol addition
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protocol was then repeated with the heart rate response being deter-
minvdR1Q mmt’ t fjpal propranolol addition. The net rate of
change in response at & and 20 mm after the final propranolol dose
were calculated from the experimental values, and these were plotted
semilogarithmically against time. The slope of the resulting straight
line was then used to extrapolate the percentage of the response-time
curve to itrs maximal value. The difference between this estimate and
the measured response was then plotted against time and the resulting
first-order rate constant was calculated by log-linear regression.
The reversibility of 9-blockade was evaluated by comparing the time
course of responsiveness after treatment of the atrial preparation with
0.3 iM propranolol for 5 mm or the addition of propranolol every 5
mm to a final concentration of 0.3 tM at 30 mm. Heart rate changes
were determined serially during the 30-mm washout period and control
measurements were performed at the beginning of each part of the
study.
Additional studies were also performed with the hydrophilic beta
adrenergic antagonist -CGP-12177 [-(±)-4-(3-t-butylamino-2-hydrox-
ypropoxy)-benzimidazole-2-one hydrochloride]. Heart rate response
was determined at 0, 5, 10, 20 and 30 mm after the addition of 30 sM
-CGP-12177 in the sequential absence and presence of either 0.3 MM
propranolol or atenolol.
Beta adrenoceptor binding of -[3H]CGP-12177. Membrane
fractions of guinea pig hearth were prepared according to the method
of Nerme et at. (1985) and the protein content was measured as
described by Lowry et at. (1951). Receptor binding of -[3H]CGP-12177
(0.25-7.95 nM) was measured according to the method of Abrahamsson
et at. (1988). Briefly, aliquots (0.1 ml) of the membrane preparation,
equivalent to 0.2 to 0.6 mg ofprotein, were incubated with --[3H]CGP-
12177 in a final volume of 0.25 ml of Tris buffer (20 mM Tris-HC1 in
0.154 M NaCl and 2 mM MgCl2, pH 7.5) containing 0.1 mM GTP.
Samples were incubated for 30 mm at 37’C in glass tubes. The reaction
was stopped by addition of 2 ml of ice-cold buffer (10 mM Tris-HC1 in
0.154 M NaCl and 2 mM MgC12, pH 7.5). Samples were filtered rapidly
through glass fiber filters (GF/C, Whatman, Maidstone, Kent, UK),
with each filter being washed twice with 5 ml of the same ice-cold
buffer. After the addition of 5 ml of Aquasol (New England Nuclear,
Boston, MA), radioactivity was determined in an automatic scintilla-
tion counter. Specific binding of -CGP-12177 was defined as the amount
bound minus that bound in the presence of 100 MM -isoproterenol.
Dissociation constants and maximum binding capacities were deter-
mined as described by Scatchard (1949).
Analytical methods. Plasma concentrations of propranolol were
measured by HPLC (Takahashi et at., 1990b). A 0.5-ml plasma sample
was extracted by adding 0.5 ml of 2 M NaOH and 0.1 ml of quinidine
sulfate solution (10 g/ml in methanol), as an internal standard, and 6
ml of diethyl ether. A 5-ml aliquot of the organic phase was evaporated
to dryness at 37#{176}Cunder a stream of nitrogen gas, the residue was
reconstituted with 100 Ml of ethanol, and a 2O-Ml aliquot was injected
onto the HPLC column. The chromatograph consisted of a pump
(Shimadzu LC-6A) connected to a Radial-PAK Cartridge CN (Waters,
10 m, 10 cm X 5 mm inside diameter) and a fluorescence detector
(Shimadzu RF-530) set at excitation and emission wavelengths of 295
and 340 nm, respectively. The mobile phase consisted of 0.83 M acetate
buffer (pH 3.0) and methanol (30:70) and the flow rate was set at 1.5
ml/min. Calibration curves over the concentration range 10-100 ng/ml
exhibited excellent linearity with a correlation coefficient of > 0.996
and a between-day coefficient of variation below 7%. The extraction
recovery ofpropranolol was 98.8 ± 1.4% (n = 5) at three concentrations,
4, 20 and 40 ng/ml.
In a preliminary study, in which propranolol (1 mg/kg) was admin-
istered i.v. to rabbits, the plasma concentrations of 4-hydroxypropran-
olol were determined by a similar HPLC-based assay (Takahashi et a!.,
1990b). Additionally, levels of the individual enantiomers of propran-
olol were measured using HPLC with a chiral stationary phase (Talc-
ahashi et at., 1988). The in vitro plasma binding of --propranolol in
rabbit plasma was also studied over the concentration range of 5 ng/
ml to 1 g/ml by ultrafiltration (Takahashi and Ogata, 1990).
Atenolol concentrations in rabbit plasma were measured by HPLC
with fluorescence detection using pindolol (5 g/ml in methanol) as an
internal standard. A 0.5-ml plasma sample was alkalized with 0.5 ml 2
M !‘.i#{246}t-I. g of NaC1 wAs AI1ediid ths  w itrctod with
5 ml ofethyl seeteta. A 4-ml aliquot ofthe organic phase was evaporated
to dryness at 37*C under a stream of nitrogen gas, the residue was
reconstituted with a lOO-Ml mobile phase and a 2O-Ml aliquot was
injected onto the HPLC column. The chromatographic instruments-
tion was the same as that described for propranolol except that exci-
tation and emission wavelengths of 280 and 320 nm were used. The
mobile phase consisted of 0.1 M phosphate buffer (pH 7.5) and meth-
anol (85:15) and the flow rate was set at 1.0 ml/min. Although the
overall recovery of atenolol was lower than that of propranolol (56.3 to
60.8% at three concentrations, 0.26, 0.52 and 1.30 g/ml), the calibra-
tion curve over this concentration range exhibited excellent linearity
with a correlation coefficient of > 0.994 and a between-day coefficient
variation of less than 4%.
Concentrations of norepinephrine and epinephrine in rabbit plasma
were determined by HPLC with electrochemical detection. The plasma
sample (1 ml) was mixed with the lO-Ml internal standard solution, 3,4-
dihydroxybenzylamine hydrobromide (250 ng/ml in 0.02N HC1) and
adsorbed onto 100 mg activated alumina in the presence of 1 ml of 1
M Tris buffer (pH 8.6). The activated alumina was rinsed 3 times with
5 ml of H20, to remove hydrophilic plasma constituents, and centri-
fuged at 1760 x g for 1 mm at O’C. The catecholamines were washed
from the activated alumina with 200 zl of 0.4 M acetic acid and a 100-
M’ aliquot of this eluate was injected onto the HPLC column. The
chromatograph consisted of a pump (Shimadzu LC-6A) fitted to a
Shim-pack CLC-ODS column (Shimadzu, 5 m, 15 cm X 6 mm inside
diameter), the temperature of which was maintained at 40’C and the
electrochemical detector (Shimadzu L-ECD-6A) potential was set at
+0.75 V. The mobile phase consisted of 80 mM phosphate buffer (pH
2.8), containing 200 mg/l of sodium 1-octanesulfonate, 0.1 M sodium
nitrate and 5 mg/l of disodium EDTA and acetonitrile (95:5) at a flow
rate of 1.0 mI/mm. Calibration curves for norepinephrine and epineph-
rine, over the concentration range 0.2 to 1.0 ng/ml, exhibited excellent
linearity with correlation coefficients of> 0.998 and 0.995, respectively,
and between-day coefficients variation of 7.0 and 5.4%, respectively.
The extraction recoveries over this concentration range were 60.4 ±
5.8% (n = 5) for norepinephrine and 55.9 ± 4.7% (n = 5) for epineph-
rine.
Data analysis. The area under the plasma concentration-time curve
and the area under the effect-time curve of the %R from 0 to 24 hr,
both calculated by using the trapezoidal rule, of the two propranolol
formulations in the human subjects were compared by using two-way
analysis of variance. The slopes of the plots of plasma concentration
against the reduction in heart rate obtained from log-linear regression
by the orthogonal least-squares method (Wagner and Ayres, 1977) were
compared by Student’s t test to determine whether they differed sig-
nificantly between the PL and LA formulations. The beta response
observed after treatment durations of 10, 20 and 40 mm (at a concen-
tration of 0.15 MM propranolol) in guinea pig atria were compared
using analysis of variance and the differences were examined by Tu-
key’s test. For all the analyses, a P value of less than .05 was considered
to be statistically significant.
Results
Pharmacodynamics in humans. The time courses of
plasma concentration and the fl-blocking activity after admin-
istration of a single p.o. dose of PL and LA are shown in figure
1. The area under the propranolol plasma level-time curve was
3-fold lower after LA than after PL (271.3 ± 181.5 yr. 92.9 ±
34.1 ng . hr . min’, P < .05). However, the area under the
effect-time curve showed no significant difference between PL
and LA (466.7 ± 190.4% - hr vs. 405.0 ± 173.0% - hr). The
slope of the response-log propranolol plasma level curve (fig.
2) after LA was significantly greater than that after PL (21.0
vs. 67.2% .ng.ml’, P < .001), suggesting that the concentra-
(A) (B)





Fig. 2. Relationship between propranolol concentration (Cp) and fi-
blocking activity (%R) after a single p.o. dose (60 mg) of PL and LA in
six healthy subjects. The equations of the fitted lines are: y = 20.98 x













Fig. 3. Relation between plasma propranolol concentration (Cp)in plasma
and il-blocking activity (%R) after iv. administration of propranolol at a
dose of 2 mg/kg infused over 0.5 (0) or 5.0 hr (#{149})in a representative
rabbit.
684 Takahashi et al. Vol. 265
i?t:3
l#{224} 2l 30 40 o so io  ab do
Cp,ng imt
tion-normalized effect after administration of the LA formu-
lation was higher than that of PL.
Pharmacodynamics in rabbits. Before conducting the
pharmacodynamic experiments in rabbits, certain pharmaco-
kinetic determinants of propranolol disposition which might
affect its fl-blocking effects were assessed. 4-Hydroxypropran-
olol, which possesses /3-blocking activity comparable to that of
the parent drug (Fitzgerald and O’Donnell, 1971), was not found
in rabbit plasma (detection limit, 1 ng/ml); the concentration
ratio of the propranolol’s enantiomers were approximately
unity during a 3-hr period after i.v. administration of (±)-
propranolol and the fraction of unbound --propranolol was
essentially constant (0.273-0.318).
In all rabbits, the concentration-response relationship ob-
tamed after propranolol infusion over 5 hr was clearly shifted
to the left of that obtained after administration of the same
dose over 0.5 hr (fig. 3). Although the plasma concentrations
of propranolol observed 2 hr after completion of the longer
Fig. 1. Time course of propranolol concen-
tration (Cp) in human plasma (A) and fi-
blocking activity (%R) (B) after a single p.o.
dose (60 mg) of PL (0) and LA (#{149})in six
healthy subjects. The data are plotted as
means ± S.D. (n = 6).
infusion were significantly lower than those after the shorter
infusion (13.2 ± 3.4 ng/ml vs. 31.3 ± 6.5 ng/ml, P < .001), the
corresponding reduction in heart rate did not differ signifi-
cantly (29.3 ± 4.4% vs. 31.9 ± 5.9%).
Representative plasma concentration-response curves with
two infusion rates of propranolol (0.4 and 4.0 mg/kg given over
-S 0.5 hr) are shown in figure 4A. The control response values up
to 6 hr after normal saline infusion did not differ significantly
from zero (0.56 ± 4.18%, n = 31 observations). Although the
interindividual variability was high, a progressive leftward shift
of the curves was observed as the infusion rate decreased in all
four rabbits. Thus, the plasma levels observed with the infusion
rate of 4 mg/kg/0.5 hr were higher than, but produced almost
the same degree of 3-blockade, as the 2- and 0.4-mg/kg/0.5 hr
infusions. The plasma propranolol concentrations at which the
13-blocking effects were essentially the same at about a 27%
reduction in heart rate were: 33.8 ± 18.4 ng/ml for 27.4 ± 2.6%
with 4 mg/kg/0.5 hr; 21.1 ± 9.2 ng/ml for 27.9 ± 2.1% with 2
mg/kg/0.5 hr; and 7.8 ± 2.8 ng/ml for 26.7 ± 1.9% with 0.4 mg/
kg/0.5 hr. Moreover, the anticlockwise hysteresis of the time
course of the response was observed at each propranolol infu-
sion rate (fig. 4A). By contrast, the time courses of the concen-
tration-response curves for atenolol, a hydrophilic beta ache-
noceptor antagonist, showed neither anticlockwise hysteresis
nor was there a leftward shift of the plasma concentration
response curve after administration at the low infusion rate
(fig. 4B).
No significant differences of plasma norepinephrine or epi-
nephrine levels with the different infusion rates of propranolol
were observed (fig. 5). However, the inter- and intraindividual
variabilities were high and, therefore, it was difficult to evaluate
from these data alone whether sympathetic activation, which
would reduce the efficiency of propranolol, had occurred after
the high infusion rate of propranolol.
A similar leftward shift of the concentration-response curve
was also observed after pretreatment with 6-hydroxydopamine
(fig. 6). The plasma propranolol concentrations at which the
reduction in heart rate (23%) was virtually identical were: 30.0
± 12.8 ng/ml for 24.1 ± 1.8% with 4 mg/kg/0.5 hr and 10.3 ±
2.8 ng/ml for 21.8 ± 6.5% with 0.4 mg/kg/0.5 hr. These results
suggest that sympathetic activation is not a major factor pro-
ducing the lower efficiency observed after the higher infusion
rate.
Pharmacodynamics in isolated guinea pig atrium. The
leftward shift of the concentration-response curve observed as
the propranolol input rate decreased from 0.3 to 0.15 tM/0.5
hr was similar to the previously obtained in vivo data from
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Fig. 4. Representative relationship between plasma
propranolol concentration (Cp) and fl-blocking activ-
ity (%R) at a propranolol dosing rate of 0.4 (0) or
4.0 (S) mg/kg/O.5 hr (A) and at an atenolol dosing
rate of 0.4 (0) or 2.0 (#{149})mg/kg/O.5 hr (B). The data
points are connected in increasing time sequence.
Fig. 5. Time courses of plasma concentration
(Conc) of norepinephnne and epinephnne in rabbit
after iv. administration of propranolol at a dosing
rate of 0.4 (0) or 4.0 (#{149})mg/kg/0.5 hr, or of normal
saline as a control (Lx). The data are plotted as
means ± S.D. (n = 4).
Fig. 6. Relationship between propranolol concentration (Cp) in plasma
and fl-blocking activity (%R) after iv. administration of propranolol at a
dosing rate of 0.4 (0) and 4.0 (#{149})mg/kg/0.5 hr in a 6-hydroxydopamine-
treated rabbit.
Fig. 7. Relationship between propranolol concentration (Cp) and 3-
blocking activity (%R) after the addition of propranolol into the medium
at a rate of 0.1 5 (0) or 0.3 (#{149})MM/O.5 hr in guinea pig atna. The data
are plotted as means ± S.D. (n = 5); ---, the corresponding response
after the addition of normal saline as a control.
hysteresis of the reduction in heart rate-time course curves for
isolated guinea pig atrium was also observed (fig. 8).
Although almost half of the level of response observed after
the 40-mm treatment was observed within 10 mm, significantly
greater effects were observed at longer times, even though the
propranolol concentration (0.15 zM) remained constant (P <
.05) (fig. 9A). From the data shown in figure 9B, the treatment
duration-dependent change in fl-blockade appeared to be a first-
Fig. 8. Time course of the relation between propranolol concentration
(Cp) and i9-blocking activity (%R) for propranolol at a dosing rate of 0.3




Fig. 9. Increase of fl-blocking activity (%R) with prolonged treatment
period by propranolol at a concentration of 0.15 MM (A) and a semi-
logarithmic plot of the difference between the maximal and the observed
response-time curve (B) in guinea pig atrium. in B was described
by the equation In y = -0.045x + 2.203 (r = -0.881 , P < .001). The











Fig. 10. Reversal of fl-blocking activity (%R) by washing after the addition
of propranolol into the medium to give a final concentration of 0.3 MM
over 5 (0) or 30 (#{149})mm (A) and a semilog plot against time of the
difference between %R obtained after 30 mm of treatment and that after
5 mm (B) in a guinea pig atrium. in B was expressed as In y =
-0.040x + 1 .586 (r = -0.81 6, P < .001). The data are plotted as means
± S.D. (n = 5).








Fig. I 1. Change in heart rate (HR) after the addition of --CGP-1 2177
(0, 30 MM) or --CGP-1 21 77 (30 MM) with the addition of propranolol (#{149},
0.3 MM) (A) or atenolol (#{149},0.3 MM) (B) in a representative guinea pig
atrium.
-I  j 02 113 U05
30 coI4M Conc, 
Fig. 12. Relationship between the concentration (Conc) of the drug in
the medium and fl-blocking activity (%R) after the addition of atenolol,
pindolol, metoprolol and penbutolol at a low (0) and a high (#{149})input rate
over 30 mm in the guinea pig atrium. The data are plotted as means ±
S.D. (n = 5).
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order process, the rate constant and half-life of which were
0.045 ± 0.01 min’ and 15.8 ± 3.3 mm, respectively.
Figure 1OA shows the differences in 3-blockade reversal
following washing after treatment with 0.3 MM propranolol for
5 and 30 mm. The effect of the 5-mm treatment, which repre-
sented almost 40% of the overall observed response after the
30-mm treatment, disappeared almost immediately, whereas
after the 30-mm treatment the fl-blocking effect decreased more
gradually. The difference between the measured effect obtained
after the 5- and 30-mm treatments was plotted semilogarithm-
ically against time (fig. lOB), and the fractional rate constant
and half-life obtained from the log-linear regression were 0.040
± 0.017 min’ and 19.2 ± 6.67 mm (n = 5), respectively.
The heart rate changes observed 30 mm after the addition of
--CGP-12177 and propranolol and --CGP-12177 and atenolol
were: -6.17 ± 1.83 (n = 7) for propranolol, which was signifi-
cantly different from zero (P < .001), and -0.40 ± 3.36 (n = 5)
for atenolol, which did not differ significantly from zero. The
lack of any difference in heart rate following the treatment
with 30 MM --CGP-12177 with or without 0.3 M atenolol (fig.
11B) was a predictable result. However, the gradual decrease
in this effect produced by 0.3 M propranolol, even in the
presence of such a high concentration of --CGP-12177 (fig.
1 1A), suggests the existence of two distinct binding sites on the
surface membrane, one of which is only accessible to lipophilic
f3-blockers. Moreover, 0.3 M isoproterenol, a hydrophilic beta-
agonist had no effect on heart rate in atria treated with 30 MM
--CGP-12177 for 30 mm (data not shown); therefore, the %R
by isoproterenol could not be obtained in this experiment, and
heart rate itself was used to assess the response to the drugs.





lipophilic characteristics were also investigated: atenolol is
hydrophilic; propranolol and penbutolol are strongly lipophilic;
and the n-octanol/pH 7.4 buffer partition coefficients of pin-
dolol and metoprolol are intermediate (Nieder et at., 1987). As
the high lipophilicity of propranolol has been suggested to be
essential for the input rate-dependent concentration-response
relationship, the effect of the input rate of these four other 3-
blockers on /3-blockade was investigated (fig. 12). Little or no
leftward shift ofthe concentration-response curve was obtained
after addition of the more hydrophilic 3-blockers at the low
input rate. In contrast, after addition of penbutolol, a depend-
ency of the relationship on the input rate was observed and the
magnitude of the effect tended to be virtually unchanged at
either the high or low input rate when the concentration was
decreased by dilution.
Binding of the hydrophilic beta adrenergic antagonist, --
[3H]CGP-12177, to the myocardial membrane of guinea pigs
appeared to involve a single site, with a B of 103.8 ± 18.6
fmol/mg of protein (n = 3) and an equilibrium dissociation
constant (Kd) of 1.67 ± 0.396 nM (n = 3). These values were
consistent with those obtained from human nonfailing myocar-
dium. Brass 110 fmol/mg of protein and Kd = 0.86 nM
(Schwinger et at., 1990), indicating a lack of species difference
in the binding properties of --CGP-12177 to the cardiac beta
receptor.
Discussion
The in vivo studies in humans and rabbits both showed that
the degree of propranolol-induced fl-blockade was considerably
greater than expected on the basis of the plasma concentration
when the drug was administered at a slower rate. Such dosing
rate dependency could involve both pharmacokinetic and phar-
macodynamical factors. The formation of an active metabo-
lite(s) might account, in part, for the observed effects. However,
neither the formation nor elimination clearance rates of 4-
hydroxypropranolol were found to be different after the admin-
istration of PL and LA preparations and, consequently, plasma
levels of this metabolite relative to those of propranolol were
similar regardless of the rate of drug delivery (Takahashi et a!.,
10 Atenolol 11
0.5 14 0.05 lii
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1990b). Moreover, in the rabbit this metabolite was undetected
in the plasma. Formation of other active metabolites such as
hio1 hd fltshol1ik drivAtivo (Ogget at, l7; W11ut
al., 1978) only contribute to a small extent to the overall
elimination of propranolol, and these compounds are also con-
siderably less potent than the parent drug (Walle et at., 1985).
Finally, the plasma levels of propranolol and its active metab-
olites, based on a nonspecific radio receptor assay of beta
adrenoceptor-blocking activity, were similar 24 hr after admmn-
istration of PL and LA formulations (Barnett et at., 1981).
Thus, it is unlikely that the presence of active metabolites can
account for the observed, rate-dependent differences in re-
sponse. Because of pronounced differences in the 9-blocking
activity of propranolol’s enantiomers (Barrett and Cullum,
1968) and the stereoselective disposition of propranolol (Tak-
ahashi et at., 1990a), especially its enantiospecific metabolism
during the first-pass effect (Silber et at., 1982), it is possible
that a formulation-dependent difference in this factor would
contribute to the observed difference in the concentration-
response relationship. However, the area under the curve ratios
of the two enantiomers have been found to be the same after
the administration of PL and LA preparations (Takahashi et
at., 1987, 1988). Furthermore, no concentration-dependent dif-
ferences in the plasma binding of the enantiomers over the
range of 30 to 300 ng/ml in humans were noted (unpublished
data). Accordingly, pharmacokinetic factors do not appear to
be contributory to the rate-dependent nature of the plasma
concentration-response relationship.
Because plasma norepinephrine concentrations after exercise
in subjects treated with a fl-blocker have been reported to be
higher than those obtained in untreated subjects (Ohnishi et
at, 1987), the increased catecholamine release from terminal
neurons, which probably is a compensatory mechanism to
counteract the beta adrenoceptor blockade, may be a possible
explanation for the lower responsiveness observed after admin-
istration of PL. Moreover, plasma norepinephrine levels during
exercise are higher after administration of a high than a low
i.v. dose of propranolol (von Bahr et at., 1982). It is not known
whether norepinephrine release and its plasma levels differ
after PL and LA administration in humans. However, the
measured norepinephrine and epinephrine plasma levels in the
rabbit were unaffected by the infusion rate of propranolol and
the infusion-rate dependency of the propranolol concentration-
response relationship was observed in rabbits pretreated with
6-hydroxydopamine, in which cardiac norepinephrine levels are
depleted by over 95% by 20 hr after the last dose (Maling et
at., 1971). Moreover, a similar rate-dependent effect was also
observed in the isolated guinea pig atrium in vitro. Accordingly,
sympathetic activation does not appear to be involved in the
dosing rate-dependent concentration-response of propranolol.
In general, the anticlockwise hysteresis, as observed in time
courses of the concentration-response curve in vivo in rabbits
and in the isolated guinea pig atrium (figs. 4 and 8), can be
explained by a disequilibrium between the plasma concentra-
tion and that at the effector site. This may occur if there is a
delay in either the access of propranolol to its site of action,
such as the existence of a deep compartment, or in the appear-
ance of the response after propranolol has bound to its the
receptor(s) (Holford and Sheiner, 1981) and if other actions of
propranolol on heart rate are delayed. Although some of the
effects on heart rate may be attributable to propranolol’s direct
membrane activity, such effects appear to be exerted at concen-
trations higher than 4 MM (Davis and Temte, 1968), which are
more than 10 times higher than the concentrations used in the
isolated guinea pig atrial studies. Moreover, if a membrane
§kiIiing fect 4d contribute significantly to the observed
cardiac response, then the apparent efficiency would be ex-
pected to be greater with the higher than with the lower infusion
rate, because the higher concentration of propranolol would
induce a proportionally greater decrease in the heart rate by
virtue of its greater membrane stabilizing effect. This is incon-
sistent with the leftward shift of the concentration-effect rela-
tionship of propranolol observed with the low infusion rate.
Accordingly, it is considered unlikely that any propranolol-
induced membrane effects are involved in the observed chron-
otropic changes.
Although the higher lipophilicity of propranolol compared
with atenolol (Nieder et at., 1987) is highly likely to be a
contributory factor to the reduced heart rate observed after the
addition of propranolol in the presence of excess --CGP-12177
(fig. 11), this is not the only difference between these drugs.
Atenolol is a selective beta-i receptor blocker, whereas pro-
pranolol acts at both beta-i and beta-2 receptors. Therefore,
beta-2-blockade induced by propranolol may contribute to the
observed effects. However, --CGP-i2177 appears to exhibit
very low beta-2 adrenoceptor selectivity. The competitive dis-
placement curve of --CGP-i2i77 and --metoprolol in a rat
myocardial membrane preparation showed that the beta-i ache-
noceptor selectivity of --CGP-i2i77 was 1.8-fold (Tsuchihashi
et at. , 1989), whereas in the presence of receptor-subtype satu-
rating concentrations of beta-i- and beta-2-selective antago-
nists, its beta- 1 adrenoceptor selectivity on rat cardiac micro-
somes was 2- to 3-fold (Nanoff et a!., i987). In view of the Kd
and Bm.. values obtained for --CGP-i2i77 on the myocardial
membranes of guinea pigs, both the subtypes of cardiac recep-
tors would be occupied completely by --CGP-i2i77 at a con-
centration of 30 MM. Moreover, only 25% of the beta receptors
in guinea pig atrium are beta-2 adrenoceptors; therefore, the
beta-i adrenoceptors would be expected to contribute more to
the positive inotropic and chronotropic responses than would
beta-2 adrenoceptors (Molenaar and Summers, 1987), and the
latter would play only a minor role in heart rate alterations. In
addition, the concentration-effect relationship of pindolol,
which like propranolol is a beta-i, beta-2 nonselective antago-
nist, showed no infusion-rate dependency (fig. 12). These re-
sults imply that the contribution of beta-2 adrenoceptor block-
ade by propranolol to its infusion rate-dependent concentra-
tion-effect relationship and the heart rate decrease observed in
the presence of excess --CGP-i2i77 was minimal.
The demonstration of an initial response observed within 5
to 10 mm of treatment of the guinea pig atrium, as well as the
hysteresis of the concentration-time course of response curve,
cannot be explained simply by a delayed action of propranolol.
Herbette et at. (1989) demonstrated that the rate of nonspecific
binding of 1,4-dihydropyridine calcium channel antagonists to
highly purified sarcoplasmic reticulum membranes, which pos-
sess virtually no specific receptors at which calcium channel
antagonists act, was almost i000 times faster than the rate of
specific binding to sarcolemmal receptors, suggesting that par-
tition into the lipid bilayer may have occurred before the drug
bound to the receptors. On the basis of these findings, the
presence of two distinct binding sites at each receptor was
proposed such that a drug might interact with these by direct
diffusion through the aqueous solvent to the more hydrophilic
site or by partitioning into the lipid bilayer and then diffusing
laterally to the lipophilic site (Herbett et a!., i986). Studies of
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the effect on heart rate in the presence of excess --CGP-i2i77
were designed to determine whether a similar situation with
propranolol exists in the isolated atrium preparation.
The --CGP-12i77 concentration of 30 MM used was ex-
tremely high compared with its Kd and B values for the beta
adrenoceptor on the myocardial membrane. On the other hand,
the Kd of --CGP-i2i77 has been reported to be 30 to 70 times
lower than the K1 value of propranolol (Wellstein et at., i985)
and also 10 to 100 times lower than the K values of other
lipophilic beta adrenergic blockers, such as timolol and alpren-
olol (Haddad et at., 1987). These data indicate that the affinity
of --CGP-i2i77 for beta receptors would be greater than those
of propranolol and other fl-blockers. Therefore, beta receptors
on the cardiac surface membrane would be occupied almost
completely with 30 MM --CGP-i2i77, despite the presence of
0.3 MM propranolol or atenolol. Even under such experimental
conditions, a reduction in heart rate caused by propranolol was
observed; by contrast, atenolol did not produce such an effect.
These results lead us to speculate that two distinct binding
sites with different lipophilicities exist on the surface mem-
brane, one of which is responsible for the effect immediately
after addition of propranolol and the other for the delayed
effect, which develops more gradually. The findings that almost
40% of the response obtained after the addition of propranolol
in concentrations of up to 0.3 MM over 30 mm occurred within
5 mm, the increase in response after the longer treatment
period and the different reversal pattern depending on the
length of propranolol treatment are all consistent with this
model. However, it cannot be determined whether there are
two receptors with different lipophilicities at different sites in
the cell or two binding sites with different lipophilicities on one
receptor. As the change in heart rate response was observed
from isoproterenol-induced tachycardia in rabbits in vivo, and
in the isolated guinea pig atrium, and isoproterenol is almost
as hydrophilic as atenolol (El Tayar et aL, i988), if the beta
receptor does exist at a lipophilic site inside the cell, the
response of propranolol produced by binding to the lipophilic
site could not be detected by competition studies with the
highly hydrophilic agonist, isoproterenol. However, if there are
two binding sites on one receptor, isoproterenol may bind to
the hydrophilic site on the surface plasma membrane, which
would provide a reasonable explanation of our data.
The hydrophilic fl-blockers --CGP-i2i77 and atenolol and
the more lipophilic propranolol may be able to bind to one of
these sites, whereas the other may be accessible only to more
hydrophobic drugs, like propranolol, probably due to the exist-
ence of a lipophilic barrier. If such a binding site is surrounded
by a hydrophilic domain, then it is possible to readily explain
the observed delayed action of propranolol. However, if such a
hydrophilic barrier exists, the responses to low concentrations
of propranolol would be abolished in the presence of excess
hydrophilic --CGP-12i77, which would saturate the binding
site completely. Moreover, hydrophilic compounds like ateno-
lol, but not propranolol, would be expected to be able to reach
this binding site via the hydrophilic barrier, in which case this
hydrophilic compound would show anticlockwise hysteresis of
the time course of its concentration-effect curve as well as the
infusion rate-dependent concentration-effect relationship. The
results obtained were inconsistent with these suggestions. How-
ever, in the presence of a lipophilic barrier, the passage of
propranolol though the lipid barriers would be faster than that
of atenolol, so propranolol could have a delayed action, even
within the 30-mm treatment period, but this would not happen
with atenolol as shown in figures 4, 8 and ii.
As discussed above, the $-blocking activity produced by bind-
ing of propranolol to the hydrophilic receptor site would appear
immediately after addition and disappear immediately after
washing, but it would take longer for fl-blockade produced by
binding to the lipophilic receptor site to appear and disappear.
Exactly what the rate constant in figure 9B represents is as yet
unknown, if the process(es) of drug diffusion to the receptor
and/or drug binding to the receptor was the rate-limiting step(s)
for the appearance of the response, then the measured rate
constant would reflect this process and the overall apparent
response would be the sum of the responses induced by pro-
pranolol binding to both the hydrophilic and lipophilic receptor
sites.
If it is assumed that the changes observed after treatment
with propranolol for 5 mm were produced by binding to the
hydrophilic receptor site and those observed after a 30-mm
treatment were induced by binding to both the hydrophilic and
lipophilic site, then the measured rate constant (fig. 10) would
represent the rate of recovery after binding to the lipophilic
site. If access of propranolol to the receptors was the rate-
limiting step, then this value would represent the overall dis-
sociation rate constant of propranolol from the lipophilic to the
aqueous binding site on the surface membrane. Moreover, in
light of the hypothesis of two binding sites with different
lipophilicities, the results with isolated guinea pig atrium (fig.
12) and those obtained from the in vivo rabbit study (fig. 4), in
which the input rate had no effect on the response relationship
with hydrophilic fl-blockers, but a marked effect with lipophilic
fl-blockers are not unexpected. The affinity of penbutolol for
the lipophilic binding site would be expected to be far greater
than that of propranolol, due to its higher lipophilicity. There-
fore, the lipophilicity of the drugs would appear to be the factor
which determines whether or not the concentration-response
relationship depends on the input rate.
In conclusion, propranolol may bind directly to receptors on
the surface plasma membrane, to which the hydrophilic beta
antagonist, --CGP-i2i77 would also bind competitively, which
would result in the immediate appearance of the reduction in
heart rate response. At the same time, propranolol may parti-
tion into the lipid bilayer and then diffuse to the lipophilic
binding site and the beta response induced by this binding
would be delayed. Accordingly, the responses induced by bind-
ing to both lipophilic and hydrophilic sites would account for
the cardiac responses observed after administration at the slow
rate, which would lead to the leftward shift of the plasma
concentration-response relationship. Therefore, when evaluat-
ing the efficacy of sustained release formulations of lipophilic
drugs that induce receptor-mediated responses, the time course
of the plasma concentration, in addition to the plasma concen-
tration itself, would be the determining factor of the responses.
Thus, time factors, such as the dosing rate in vivo and duration
of exposure in vitro, should be necessary to consider when
designing study protocols. Previously, no studies have indicated
that the existence of two drug binding sites with different
lipophilicities is the major determinant of the anticlockwise
hysteresis of the time course of the response. Further studies
are therefore needed to distinguish the lipophilic from the
hydrophilic binding site of the drug on the plasma membrane
and to establish whether fl-blocking activity is induced by drug
binding to the lipophilic receptor site.
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